Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus

Phase 3 Unknown 340 enrolled Scotmann Pharmaceuticals University of Health Sciences Lahore · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of the VETA trial is to verify the potential beneficial effects of the combination of micronutrients namely Vitamin D3 and K2 in combination with oral antihyperglycemic Empagliflozin in Diabetes Mellitus

Timeline

Start: 2022-08
Primary completion: 2023-02
Completion: 2023-06

Publications

Background Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cholecalciferol	Other / unclassified	2000 iu	—
Comparator	Empagliflozin	Small molecule	10 mg	Oral
Subject	Vitamin K2	Unknown	100 ug	—

Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus

Summary

Timeline

Publications

Drugs

Indications